Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

While Alnylam has not released an official statement regarding the financial impact of the CHMP’s recommendation, investors have responded favorably to the news. The stock’s upward movement reflects ...

The EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion, recommending a change to the terms of the marketing ...

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis ...

Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday, May 1, 2025, ...

The company has developed several FDA-approved therapies including Amvuttra, Onpattro, Givlaari, and more. On April 9, Joseph Stringer from Needham maintained a Buy rating on the stock ...

Experts discuss the evidence supporting the National Lipid Association’s (NLA) recommendation for universal lipoprotein(a) (Lp[a]) measurement and evaluate how compelling this evidence is from a ...

Alnylam Pharmaceuticals (NASDAQ:ALNY) recently received FDA approval for AMVUTTRA in the treatment of ATTR cardiomyopathy and projected significant revenue growth in the coming years. The company is ...

With an increased need for operational efficiency, while also leveraging new technologies such as AI, the landscape of clinical operations is evolving, as our February issue explores.

Amvuttra (vutrisiran) Transthyretin-directed small interfering RNA therapeutic Treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce ...